Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication (RETRO-HP)

Yueyue Li

Status: Completed

Conditions: Helicobacter Pylori Infection

Treatments: Other: This study is a retrospective study, and all data have been collected in advance with no active intervention required.

Study type: Observational

Funder types: Other

Identifiers

NCT07167511

202508

Details and patient eligibility

About

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify factors influencing treatment failure. A multicenter retrospective analysis was conducted and study outcomes included eradication rates and incidence of adverse events.

Enrollment: 1,730 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients aged 18-70 years, regardless of gender;
• absent history of receiving H. pylori eradication therapy;
• diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

Exclusion criteria

• patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
• patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.

Trial design

1,730 participants in 2 patient groups

vonoprazan-based quadruple therapies

Treatment:

Other: This study is a retrospective study, and all data have been collected in advance with no active intervention required.

tegoprazan-based quadruple therapies

Treatment:

Other: This study is a retrospective study, and all data have been collected in advance with no active intervention required.